U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07324018) titled 'Spirulina Derivative for Radiation Esophagitis' on Dec. 03, 2025.
Brief Summary: To evaluate the efficacy and safety of a Spirulina-derived product in preventing and treating radiation-induced esophagitis in esophageal cancer patients undergoing intensity-modulated radiotherapy (IMRT).
Study Start Date: Jan. 01
Study Type: INTERVENTIONAL
Condition:
Radiation-induced Esophagitis
Intervention:
DRUG: Hydrogel of spirulina-derived exosomes.
An oral hydrogel formulated with purified spirulina-derived exosomes.
DRUG: Hydrogel of placebo
The placebo oral hydrogel will be formulated with inactive ingredients matched in appearance an...